Cargando…
Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine
Pancreatic ductal adenocarcinoma (PDAC) is among the most deadly solid tumours. This is due to a generally late-stage diagnosis of a primarily treatment-refractory disease. Several large-scale sequencing and mass spectrometry approaches have identified key drivers of this disease and in doing so hig...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580874/ https://www.ncbi.nlm.nih.gov/pubmed/30396902 http://dx.doi.org/10.1136/gutjnl-2018-316822 |